Merck Group FY21 EBITDA Pre Rises; Net Sales Up 13.8% Organically

Merck (MKGAY.PK) said fiscal 2021 was a year of record growth and margin expansion. Life Science was the main growth engine in 2021. For 2022, the company expects strong organic growth of net sales and EBITDA pre.

Fiscal 2021 EBITDA pre increased by 17.3% to 6.1 billion euros from prior year. EBITDA pre margin rose by 1.3 percentage points to 31.0%. EBITDA pre grew organically by 18.1% in 2021. Excluding a one-time effect in 2020, EBITDA pre rose organically by 27.0%. Earnings per share pre, increased by 30.1% to 8.72 euros.

Group net income increased 53.7% to 3.1 billion euros. Earnings per share was 7.03 euros compared to 4.57 euros.

Group net sales increased by 12.3% to 19.7 billion euros. Group net sales rose organically by 13.8%.

Merck expects strong organic growth of net sales in fiscal 2022, driven by all business sectors, particularly by Life Science. For EBITDA pre in fiscal 2022, the company expects strong organic growth.

"Our focus is and remains our medium-term goal: around 25 billion euros in Group sales by 2025," said Belén Garijo, CEO of Merck.

The Executive Board and the Supervisory Board will propose to the Annual General Meeting on April 22, 2022, a dividend of 1.85 euros per share, an increase of 0.45 euros over the previous year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MTD Products Inc. is recalling 1,774 units of walk-behind self-propelled lawn mowers for potential risk of fire hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the lawn mower can leak fuel when it is stored in the upright (vertical) storage position to pose a fire hazard. Nike Inc. announced its plans to exit the Russian market completely following Russia's ongoing war against Ukraine, reports said. The sportswear major, with more than 100 stores in the country, had suspended operations there in March. Earlier in March, while suspending operations temporarily, the company had said its customers that it couldn't guarantee product shipments. The U.S. Food and Drug Administration unveiled its action plan to advance drug development for rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis or ALS, in five years. The FDA plans specific actions such as regulatory science initiatives, enhancements to existing programs and new policy initiatives for the purpose. It will use public-private partnerships...
Follow RTT